Terumo Corp. (4543) posts record profits, issues robust outlook for current fiscal year
Terumo Corp. shares climbed on Monday, 18 May 2026, after the Japanese medical device manufacturer reported record profits for its fiscal year ending March 2026 and issued a robust outlook for the current fiscal year. The company's stock is trading up 15.4% at ¥2,219, following a previous close of ¥1,922.
Terumo announced consolidated sales of ¥1,130 billion for the fiscal year ended March 2026. Operating profit reached a record ¥176.3 billion, an 11.8% increase from the prior year. For the fiscal year ending March 2027, the company projects operating profit to rise significantly by 27.3% to ¥224.5 billion, exceeding market consensus expectations.
This optimistic forecast reflects Terumo's confidence in future growth, driven by organic expansion, new product introductions, and strategic acquisitions. The company's competitive advantage within the medical device sector underpins these projections.
Terumo's Surpassing Forecasts Drive Share Price Surge
Terumo Corp. is a major Japanese medical technology company, deeply embedded in healthcare worldwide. They design and manufacture sophisticated medical devices, pharmaceuticals, and regenerative medicine products. Their offerings range from cardiovascular tools like catheters and artificial heart-lung machines to diabetes management products such as blood glucose meters, and solutions for blood transfusion and cell therapy, serving hospitals, clinics, and patients globally.
The primary driver behind today's significant movement in Terumo's stock is a robust earnings forecast for the upcoming fiscal year, which dramatically exceeded market expectations. While the company reported consolidated sales of ¥1,130 billion and a record operating profit of ¥176.3 billion for the fiscal year ending March 2026, investors focused on the projection for the fiscal year ending March 2027. Terumo anticipates an operating profit of ¥224.5 billion, representing a substantial 27.3% increase from the previous year, a figure considerably higher than the average analyst prediction.
This unexpectedly strong outlook has propelled Terumo's share price. It is currently trading at ¥2,219, marking a 15.4% increase from yesterday's close of ¥1,922, as investors value the company's enhanced future earnings potential.
Consider a scenario where a renowned research lab announces a breakthrough that promises to revolutionise a particular industry. While the market expected progress, the lab's specific findings and projected impact are far more significant than anyone had dared to hope. This unexpected leap forward would immediately cause a surge of excitement and investment, as people rush to be part of what is now clearly a much bigger and more lucrative future.
Terumo Corp.
Terumo Corporation (4543) is a global manufacturer and distributor of medical products and equipment, operating across three core segments. Its Cardiac and Vascular Company provides a comprehensive range of devices, including angiographic catheters, PTCA balloon catheters, and coronary stents, alongside solutions for cerebral aneurysm and ischemic stroke treatment. The Medical Care Solutions Company focuses on general medical devices such as syringes, infusion pumps, and blood glucose monitoring systems, also offering contract manufacturing for prefilled syringes. Finally, the Blood and Cell Technologies Company specialises in blood bags, automated blood processing systems, and cell expansion technologies. Established in 1921 as Sekisen Ken-onki Corporation, the company adopted its current name in October 1974 and is headquartered in Tokyo, Japan.